Sickle-cell disease

Lancet

Volumn 364, Issue 9442, 2004, Pages 1343-1360

  Stuart, Marie J ^a,c   Nagel, Ronald L ^b  

^a Division of Hematology   (United States)

^b Division of Hematology   (United States)

^c THOMAS JEFFERSON UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2,2 BIS(4 FLUOROPHENYL) 2 PHENYLACETAMIDE; ABCIXIMAB; ALPHA ADRENERGIC RECEPTOR STIMULATING AGENT; ANTIINFLAMMATORY AGENT; ANTIOXIDANT; ARGININE; BETA ADRENERGIC RECEPTOR STIMULATING AGENT; BLOCKING AGENT; CLOTRIMAZOLE; DIETHYLSTILBESTROL; DIPYRIDAMOLE; ETILEFRINE; HEMOGLOBIN S; HYDROXYUREA; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; ION CHANNEL; MACROLIDE; MONOCLONAL ANTIBODY; NARCOTIC ANALGESIC AGENT; NITRIC OXIDE; NONSTEROID ANTIINFLAMMATORY AGENT; OPIATE; PENICILLIN G; PSEUDOEPHEDRINE; PYROGLUTAMATE MAGNESIUM; SILDENAFIL; TERBUTALINE; UNCLASSIFIED DRUG;

ACUTE CHEST SYNDROME; ANEMIA; APLASIA; BLOOD TRANSFUSION; CARCINOGENESIS; CELL ACTIVATION; CELL ADHESION; CEREBROVASCULAR ACCIDENT; CLINICAL FEATURE; CONFERENCE PAPER; CONSERVATIVE TREATMENT; DIAGNOSTIC TEST; ENDOTHELIUM CELL; ERYTHROCYTE; GENE THERAPY; GENETIC EPIDEMIOLOGY; GENOTYPE; HAND FOOT SYNDROME; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HOMEOSTASIS; HUMAN; IMMUNIZATION; ION TRANSPORT; LABORATORY TEST; LEUKEMIA; LEUKOCYTOSIS; LIPID BILAYER; MOLECULAR MECHANICS; NONHUMAN; PATHOPHYSIOLOGY; PEDIATRICIAN; PERIOPERATIVE PERIOD; PHENOTYPE; PLASMODIUM FALCIPARUM; POLYMERIZATION; PREGNANCY; PRIAPISM; PRIORITY JOURNAL; SICKLE CELL ANEMIA; SPLEEN; TRANSGENIC MOUSE;

EID: 5044239523     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(04)17192-4     Document Type: Conference Paper

References (175)

1. Onwubalili JK. Sickle-cell anaemia: an explanation for the ancient myth of reincarnation in Nigeria. Lancet. 322:1983;503-505
2. Herrick JB. Peculiar elongated and sickled-shaped red blood corpuscles in a case of severe anemia. Arch Intern Med. 6:1910;517-521
3. Pauling L, Itano HA, Singer SJ, Wells IC. Sickle cell anemia: a molecular disease. Science. 110:1949;543-548
4. Ingram VM. Gene mutations in human haemoglobin: the chemical difference between normal and sickle haemoglobin. Nature. 180:1957;326-328
5. Perutz MF, Rossmann MG, Cullis AF, et al. Structure of haemoglobin: a three-dimensional Fourier synthesis at 5·5Å resolution obtained by x-ray analysis. Nature. 185:1960;416-422
6. Watson J, Stahman AW, Billelo FP. The significance of the paucity of sickle cells in newborn negro infants. Am J Med Sci. 215:1948;419-423
7. Nagel RL. Malaria and hemoglobinopathies. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of hemoglobin: genetics, pathophysiology, clinical management. 2001;Cambridge University Press, Cambridge, UK
8. Orkin SH, Kazazian HH Jr, Antonarakis SE, et al. Linkage of beta-thalassemia mutations and beta-globin gene polymorphisms with DNA polymorphisms in human beta-globin gene cluster. Nature. 296:1982;627-631
9. Nagel RL, Steinberg MH. Genetic variability in sickle cell anemia. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of hemoglobin: genetics, pathophysiology, clinical management. 2001;117-130 Cambridge University Press, Cambridge, UK
10. Chui DH, Dover GJ. Sickle cell disease: no longer a single gene disorder. Curr Opin Pediatr. 13:2001;22-27
11. Old JM. DNA-based diagnosis of hemoglobin. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of hemoglobin: genetics, pathophysiology, clinical management. 2001;941-957 Cambridge University Press, Cambridge, UK
12. Ducrocq R, Pascaud O, Bevier A, Finet C, Benkerrou M, Elion J. Strategy linking several analytical methods of neonatal screening for sickle cell disease. J Med Screen. 8:2001;8-14
13. Steinberg MH. Management of sickle cell disease. N Engl J Med. 340:1999;1021-1030
14. Bookchin RM, Balazs T, Nagel RL, Tellez I. Polymerisation of haemoglobin SA hybrid tetramers. Nature. 269:1977;526-527
15. 2 on the polymerization of hemoglobin S. Proc Natl Acad Sci USA. 76:1979;670-672
16. Eaton WA, Hofrichter J. Sickle cell hemoglobin polymerization. Adv Protein Chem. 40:1990;63-279
17. Ferrone F, Nagel RL. Sickle hemoglobin polymerization. Steinberg MH, Forget BG, Higgs DR, Nagel RL. Disorders of hemoglobin: genetics, pathophysiology, clinical management. 2001;577-610 Cambridge University Press, Cambridge, UK
18. Kaul DK, Fabry ME, Nagel RL. Microvascular sites and characteristics of sickle cell adhesion to vascular endothelium in shear flow conditions: pathophysiological implications. Proc Natl Acad Sci USA. 86:1989;3356-3360
19. 3 (7E3 and LM609) inhibit sickle red blood cell-endothelial interactions induced by platelet-activating factor. Blood. 95:2000;368-374
20. Turhan A, Weiss LA, Mohandas N, Coller BS, Frenette PS. Primary role for adherent leucocytes in sickle cell vascular occlusion: a new paradigm. Proc Natl Acad Sci USA. 99:2002;3047-3051
21. Bookchin RM, Lew VL. Sickle red cell dehydration: mechanisms and interventions. Curr Opin Hematol. 9:2002;107-110
22. Gibson JS, Ellory JC. Membrane transport in sickle cell disease. Blood Cells Mol Dis. 28:2002;303-314
23. Brugnara C. Therapeutic strategies for prevention of sickle cell dehydration. Blood Cells Mol Dis. 27:2001;71-80
24. Hoover R, Rubin R, Wise G, Warren R. Adhesion of normal and sickle erythrocytes to endothelial monolayer cultures. Blood. 54:1979;872-876
25. Hebbel RP, Boogaerts MA, Eaton JW, Steinberg MH. Erythrocyte adherence to endothelium in sickle cell anemia: a possible determinant of disease severity. N Engl J Med. 302:1980;992-995
26. 1 and glycoprotein IV (CD36) are expressed on circulating reticulocytes in sickle cell anemia. Blood. 82:1993;3548-3555
27. 1-integrin expression on sickle reticulocytes: vascular cell adhesion molecule-1-dependent binding to endothelium. Blood. 82:1993;1891-1899
28. Gee BE, Platt OS. Sickle reticulocytes adhere to VCAM-1. Blood. 85:1995;268-274
29. Setty BN, Stuart MJ. Vascular cell adhesion molecule-1 is involved in mediating hypoxia-induced sickle red blood cell adherence to endothelium: potential role in sickle cell disease. Blood. 88:1996;2311-2320
30. Gupta K, Gupta P, Solovey A, Hebbel RP. Mechanism of interaction of thrombospondin with human endothelium and inhibition of sickle erythrocyte adhesion to human endothelial cells by heparin. Biochim Biophys Acta. 1453:1999;63-73
31. Brittain JE, Mlinar KJ, Anderson CS, Orringer EP, Parise LV. Integrin-associated protein is an adhesion receptor on sickle red blood cells for immobilized thrombospondin. Blood. 97:2001;2159-2164
32. Wick TM, Moake JL, Udden MM, McIntire LV. Unusually large von Willebrand factor multimers preferentially promote young sickle and non-sickle erythrocyte adhesion to endothelial cells. Am J Hematol. 42:1993;284-292
33. Hillery CA, Du MC, Montgomery RR, Scott JP. Increased adhesion of erythrocytes to components of the extracellular matrix: isolation and characterization of a red blood cell ligand that binds thrombospondin and laminin. Blood. 87:1996;4879-4886
34. Manodori AB, Barabino GA, Lubin BH, Kuypers FA. Adherence of phosphatidylserine-exposing erythrocytes to endothelial matrix thrombospondin. Blood. 95:2000;1293-1300
35. Setty BNY, Kulkarni S, Stuart MJ. Role of erythrocyte phosphatidylserine in sickle red cell-endothelial adhesion. Blood. 99:2002;1564-1571
36. Udani M, Zen Q, Cottman M, et al. Basal cell adhesion molecule/lutheran protein: the receptor critical for sickle cell adhesion to laminin. J Clin Invest. 101:1998;2550-2558
37. Hines PC, Zen Q, Burney SN, et al. Novel epinephrine and cyclic AMP-mediated activation of BCAM-Lu-dependent sickle (SS) RBC adhesion. Blood. 101:2003;3281-3287
38. Manodori AB, Matsui NM, Chen JY, Embury SH. Enhanced adherence of sickle erythrocytes to thrombin-treated endothelial cells involves interendothelial cell gap formation. Blood. 92:1998;3445-3454
39. Matsui NM, Borsig L, Rosen SD, Yaghmai M, Varki A, Embury SH. P-selectin mediates the adhesion of sickle erythrocytes to endothelium. Blood. 98:2001;1955-1962
40. Tait JF, Gibson D. Measurement of membrane phospholipid asymmetry in normal and sickle-cell erythrocytes by means of annexin V binding. J Lab Clin Med. 123:1994;741-748
41. Kuypers FA, Lewis RA, Hua M, et al. Detection of altered membrane phospholipid asymmetry in subpopulations of human red blood cells using fluorescently labeled annexin V. Blood. 87:1996;1179-1187
42. de Jong K, Larkin SK, Styles LA, Bookchin RM, Kuypers FA. Characterization of the phosphatidylserine-exposing subpopulation of sickle cells. Blood. 98:2001;860-867
43. Setty BN, Kulkarni S, Rao AK, Stuart MJ. Fetal hemoglobin in sickle cell disease: relationship to erythrocyte phosphatidlyserine exposure and coagulation activation. Blood. 96:2000;1119-1124
44. Yasin Z, Witting S, Palascak MB, Joiner CH, Rucknagel DL, Franco RS. Phosphatidylserine externalization in sickle red blood cells: associations with cell age, density, and haemoglobin F. Blood. 102:2003;365-370
45. Franck PF, Bevers EM, Lubin BH, et al. Uncoupling of the membrane skeleton from the lipid bilayer: the cause of accelerated phospholipid flip-flop leading to an enhanced procoagulant activity of sickled cells. J Clin Invest. 75:1985;183-190
46. Zwaal RF, Schroit AJ. Pathophysiologic implications of membrane phospholipid asymmetry in blood cells. Blood. 89:1997;1121-1132
47. Miller ST, Sleeper LA, Pegelow CH, et al. Prediction of adverse outcomes in children with sickle cell disease. N Engl J Med. 342:2000;83-89
48. Platt OS, Brambilla DJ, Rosse WF, et al. Mortality in sickle cell disease: life expectancy and risk factors for early death. N Engl J Med. 330:1994;1639-1644
49. Castro O, Brambilla DJ, Thorington B, et al. The acute chest syndrome in sickle cell disease: incidence and risk factors. Blood. 84:1994;643-649
50. Kinney TR, Sleeper LA, Wang WC, et al. Silent cerebral infarcts in sickle cell anemia: a risk factor analysis. Pediatrics. 103:1999;640-645
51. Grigg AP. GCSF-induced sickle cell crisis and multiorgan dysfunction in a patient with compound heterozygous sickle cell/beta+ thalassemia. Blood. 97:2001;3998-3999
52. Lard LR, Mul FP, de Haas M, Roos D, Duits AJ. Neutrophil activation in sickle cell disease. J Leukoc Biol. 66:1999;411-415
53. Fadlon E, Vordermeier S, Pearson TC, et al. Blood polymorphonuclear leucocytes from the majority of sickle cell patients in the crisis phase of the disease show enhanced adhesion to vascular endothelium and increased expression of CD64. Blood. 91:1998;226-274
54. 2 in sickle cell disease. Blood. 91:1998;3423-3429
55. 4 to disease pathophysiology. J Lab Clin Med. 139:2002;80-89
56. Frenette PS. Sickle cell vaso-occlusion: multistep and multicellular paradigm. Curr Opin Hematol. 9:2002;101-106
57. Kaul DK, Hebbel RP. Hypoxia/reoxygenation causes inflammatory response in transgenic sickle mice but not in normal mice. J Clin Invest. 106:2000;411-420
58. Charache S, Terrin ML, Moore RD, et al. Effect of hydroxyurea on frequency of painful crises in sickle cell anemia. N Engl J Med. 332:1995;1317-1322
59. 2 production of polymorphonuclear neutrophils from patients with sickle cell anemia. Blood. 99:2002;2297-2303
60. Stuart MJ, Setty BN. Hemostatic alterations in sickle cell disease: relationships to disease pathophysiology. Pediatr Path Mol Med. 20:2001;27-46
61. Wun T, Paglieroni T, Tablin F, Welborn J, Nelson K, Cheung A. Platelet activation and platelet-erythrocyte aggregates in patients with sickle cell disease. J Lab Clin Med. 129:1997;507-516
62. Setty BN, Rao AK, Stuart MJ. Thrombophilia in sickle cell disease: the red cell connection. Blood. 98:2001;3228-3233
63. Greenberg J, Ohene-Frempong K, Halus J, Way C, Schwartz E. Trial of low doses of aspirin as prophylaxis in sickle cell disease. J Pediatr. 102:1983;781-784
64. Semple MJ, Al-Hasani SF, Kioy P, Savidge GF. A double-blind trial of ticlopidine in sickle cell disease. Thromb Haemost. 51:1984;303-306
65. Tomer A, Harker LA, Kasey S, Eckman JR. Thrombogenesis in sickle cell disease. J Lab Clin Med. 137:2001;398-407
66. Stockman JA, Nigro MA, Mishkin MM, Oski FA. Occlusion of large vessels in sickle-cell anemia. N Engl J Med. 287:1972;846-849
67. Rothman SM, Fulling KH, Nelson JS. Sickle cell anemia and central nervous system infarction: a neuropathological study. Ann Neurol. 20:1986;684-690
68. Sowemimo-Coker SO, Meiselman HJ, Francis RB Jr. Increased circulating endothelial cells in sickle cell crises. Am J Hematol. 31:1989;263-265
69. Duits AJ, Pieters RC, Saleh AW, et al. Enhanced levels of soluble VCAM-1 in sickle cell patients and their specific increment during vasoocclusive crisis. Clin Immunol Immunopathol. 81:1996;96-98
70. Stuart MJ, Setty BN. Sickle cell acute chest syndrome: pathogenesis and rationale for treatment. Blood. 94:1999;1555-1560
71. Solovey A, Lin Y, Browne P, Choong S, Wayner E, Hebbel RP. Circulating activated endothelial cells in sickle cell anemia. N Engl J Med. 337:1997;1584-1590
72. Solovey A, Gui L, Key NS, Hebbel RP. Tissue factor expression by endothelial cells in sickle cell anemia. J Clin Invest. 101:1998;1899-1904
73. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 97:2001;1937-1941
74. Westerman MP, Green D, Gilman-Sachs A, et al. Antiphospholipid antibodies, proteins C and S, and coagulation changes in sickle cell disease. J Lab Clin Med. 134:1999;352-362
75. Key NS, Shingaard A, Dandelet L, et al. Whole blood tissue factor procoagulant activity is elevated in patients with sickle cell disease. Blood. 91:1998;4216-4223
76. Robinson SD, Frenette PS, Rayburn H, et al. Multiple, targeted deficiencies in selectins reveal a predominant role for P-selectin in leucocyte recruitment. Proc Natl Acad Sci USA. 96:1999;11452-11457
77. Frenette PS, Johnson RC, Hynes RO, Wagner DD. Platelets roll on stimulated endothelium in vivo: an interaction mediated by endothelial P-selectin. Proc Natl Acad Sci USA. 92:1995;7450-7454
78. Matsui NM, Varki A, Embury SH. Heparin inhibits the flow adhesion of sickle red blood cells to P-selectin. Blood. 100:2002;3790-3796
79. Tomer A, Kasey S, Connor WE, Clark S, Harker LA, Eckman JR. Reduction of pain episodes and prothrombotic activity in sickle cell disease by dietary n-3 fatty acids. Thromb Haemost. 85:2001;966-974
80. Styles L, de Jong K, Vichinsky E, et al. Increased RBC phosphatidylserine exposure in sickle cell disease patients at risk for stroke by transcranial doppler screening. Blood 1997; 90: 604 (abstr).
81. Nagel RL, Fabry ME. The panoply of animal models for sickle cell anemia. Br J Haematol. 112:2001;19-25
82. Gladwin T, Schechter A. Nitric oxide therapy in sickle cell disease. Semin Hematol. 38:2001;333-342
83. Ballas SK. Neurobiology and treatment of pain. Embury SH, Hebbel RP, Mohandas N, Steinberg MH. Sickle cell disease: basic principles and clinical practice. 1994;745-772 Raven Press, New York
84. Platt OS, Thorington BD, Brambilla DJ. Pain in sickle cell disease: rates and risk factors. N Engl J Med. 325:1991;11-16
85. Dampier C, Ely B, Brodecki D, O'Neal P. Characteristics of pain managed at home in children and adolescents with sickle cell disease by using diary self-reports. J Pain. 3:2002;461-470
86. Todd KH, Samaroo N, Hoffman JR. Ethnicity as a risk factor for inadequate emergency room analgesia. JAMA. 269:1993;1537-1539
87. Benjamin LJ, Swinson GI, Nagel RL. Sickle cell anemia day hospital: an approach for the management of uncomplicated painful crises. Blood. 95:2000;1130-1136
88. Ware MA, Hambleton I, Ochaya I, Serjeant GR. Day-care management of sickle cell painful crisis in Jamaica: a model applicable elsewhere? Br J Haematol. 104:1999;93-96
89. Jacobson SJ, Kopecky EA, Joshi P, Babul N. Randomised trial of oral morphine for painful episodes of sickle cell disease in children. Lancet. 350:1997;1358-1361
90. Rees DC, Olujohungbe AD, Parker NE, et al. Guidelines for management of the acute painful crisis in sickle cell disease. Br J Haematol. 120:2003;744-752
91. Vichinsky EP, Styles LA, Colangelo H, Wright EC, Castro O, Nickerson B. Acute chest syndrome in sickle cell disease: clinical presentation and course. Blood. 89:1997;1787-1792
92. Vichinsky EP, Neumayr LD, Earles AN, et al. Causes and outcomes of the acute chest syndrome in sickle cell disease. N Engl J Med. 342:2000;1855-1865
93. Stuart MJ, Setty BN. Acute chest syndrome of sickle cell disease: new light on an old problem. Curr Opin Hematol. 8:2001;111-122
94. Lowenthal EA, Wells A, Emanuel P, Player R, Prchal JT. Sickle cell acute chest syndrome associated with parvovirus B19 infection: case series and review. Am J Hematol. 51:1996;207-213
95. Bellet PS, Kalinyak KA, Shukla R, Gelfand MJ, Rucknagel DL. Incentive spirometry to prevent acute pulmonary complications in sickle cell disease. N Engl J Med. 333:1995;699-703
96. Aldrich TK, Dhuper SK, Patwa NS, et al. Pulmonary entrapment of sickle cells: the role of regional alveolar hypoxia. J Appl Physiol. 80:1996;531-539
97. 2 levels in acute chest syndrome of sickle cell disease. Blood. 87:1996;2573-2578
98. 2 predicts impending acute chest syndrome in sickle cell disease. Blood. 96:2000;3276-3278
99. 2 isoprostanes in the acute chest syndrome of sickle cell disease as a marker of oxidative stress. Am J Respir Crit Care Med. 164:2001;1248-1252
100. Morris CR, Kuypers FA, Larkin S, Vichinsky EP, Styles LA. Patterns of arginine and nitric oxide in patients with sickle cell disease with vaso-occlusive crisis and acute chest syndrome. J Pediatr Hemat Oncol. 22:2000;515-520
101. de Francheschi L, Baron A, Scarpa A, et al. Inhaled nitric oxide protects transgenic SAD mice from sickle cell disease-specific lung injury induced by hypoxia/reoxygenation. Blood. 102:2003;1087-1896
102. Sullivan KJ, Kissoon N, Duckworth LJ, et al. Low exhaled nitric oxide and a polymorphism in the NOS I gene is associated with acute chest syndrome. Am J Respir Crit Care Med. 164:2001;2186-2190
103. Pearson HA, Gallagher D, Chilcote R, et al. Developmental pattern of splenic dysfunction in sickle cell disorders. Pediatrics. 76:1985;392-397
104. Kinney TR, Ware RE, Schultz WH, Filston HC. Long-term management of splenic sequestration in children with sickle cell disease. J Pediatr. 117:1990;194-199
105. Rao S, Gooden S. Splenic sequestration in sickle cell disease: role of transfusion therapy. Am J Pediatr Hematol Oncol. 7:1985;298-301
106. Serjeant GR, Serjeant BE, Thomas PW, Anderson MJ, Patou G, Pattison JR. Human parvovirus infection in homozygous sickle cell disease. Lancet. 341:1993;1237-1240
107. Ohene-Frempong K, Weiner SJ, Sleeper LA, et al. Cerebrovascular accidents in sickle cell disease: rates and risk factors. Blood. 91:1998;288-294
108. Merkel KH, Ginsberg PL, Parker JC Jr, Post MJ. Cerebrovascular disease in sickle cell anemia: a clinical, pathological, and radiological correlation. Stroke. 9:1978;45-52
109. Styles LA, Hoppe C, Klitz W, Vichinsky E, Lubin B, Trachtenberg E. Evidence for HLA-related susceptibility for stroke in children with sickle cell disease. Blood. 95:2000;3562-3567
110. Hoppe C, Klitz W, Noble J, Vigil L, Vichinsky E, Styles L. Distinct HLA associates by stroke subtype in children with sickle cell anemia. Blood. 101:2003;2865-2869
111. Taylor JG, Tang DC, Savage SA, et al. Variants in the VCAM-1 gene and risk for symptomatic stroke in sickle cell disease. Blood. 100:2002;4303-4309
112. Kirkham FJ, Hewes DKM, Prengler M, Wade A, Lane R, Evans JPM. Nocturnal hypoxaemia and central-nervous-system events in sickle-cell disease. Lancet. 357:2001;1656-1659
113. Setty BNY, Stuart MJ, Dampier C, Brodecki D, Allen JL. Hypoxaemia in sickle cell disease: biomarker modulation and relevance to pathophysiology. Lancet. 362:2003;1450-1455
114. Pegelow CH, Adams RJ, McKie V, et al. Risk of recurrent stroke in patients with sickle cell disease treated with erythrocyte transfusions. J Pediatr. 126:1995;896-899
115. Telen MJ. Principles and problems of transfusion in sickle cell disease. Semin Hematol. 38:2001;315-323
116. Vichinsky E, Luban NL, Wright E, et al. Prospective RBC phenotype matching in a stroke prevention trial in sickle cell disease: a multicenter transfusion trial. Transfusion. 41:2001;1086-1092
117. Cohen AR, Martin MB, Silber JH, Kim HC, Ohene-Frempong K, Schwartz E. A modified transfusion program for prevention of stroke in sickle cell disease. Blood. 79:1992;1657-1661
118. Ware RE, Zimmerman SA, Schultz WH. Hydroxyurea as an alternative to blood transfusions for the prevention of recurrent stroke in children with sickle cell disease. Blood. 94:1999;3022-3026
119. Walters MC, Storb R, Patience M, et al. Impact of bone marrow transplantation for symptomatic sickle cell disease: an interim report. Blood. 95:2000;1918-1924
120. Adams RJ. Stroke prevention in sickle cell disease. Curr Opin Hematol. 7:2000;101-105
121. Adams RJ, McKie VC, Hsu L, et al. Prevention of a first stroke by transfusions in children with sickle cell anemia and abnormal results on transcranial doppler ultrasonography. N Engl J Med. 339:1998;5-11
122. Cohen AR. Sickle cell disease: new treatments, new questions. N Engl J Med. 339:1998;42-44
123. Zimmerman SA, Schultz WH, Davis JS, et al. Hydroxyurea therapy lowers transcranial doppler velocities in children with sickle cell disease. Presented at the 30th National Sickle Cell Meeting, Washington, DC, USA. September, 2002; abstr 26.
124. Miller ST, Macklin EA, Pegelow CH, et al. Silent infarction as a risk factor for overt stroke in children with sickle cell anemia: a report from the Cooperative Study of sickle cell disease. J Pediatr. 139:2001;385-390
125. Melman A, Serels S. Priapism. Int J Impot Res. 12:(suppl 4):2000;S133-S139
126. Mantadakis E, Ewalt DH, Cavender JD, Rogers ZR, Buchanan GR. Outpatient penile aspiration and epinephrine irrigation for young patients with sickle cell anemia and prolonged priapism. Blood. 95:2000;78-82
127. Gbadoe AD, Atakouma Y, Kusiaku K, Assimadi JK. Management of sickle cell priapism with etilefrine. Arch Dis Child. 85:2001;52-53
128. Kassim AA, Fabry ME, Nagel RL. Acute priapism associated with the use of sildenafil in a patient with sickle cell trait. Blood. 95:2000;1878-1879
129. Bialecki ES, Bridges KR. Sildenafil relieves priapism in patients with sickle cell disease. Am J Med. 113:2002;252
130. Cunningham G, Lorey F, Kling S, et al. Mortality among children with SCD identified by newborn screening during 1990-94 in California, Illinois, and New York. MMWR Morb Mortal Wkly Rep. 47:1998;169-172
131. Diallo D, Tchernia G. Sickle cell disease in Africa. Curr Opin Hematol. 9:2002;111-116
132. Vichinsky E. New therapies in sickle cell disease. Lancet. 360:2002;629-631
133. Vichinsky EP, Haberkern CM, Neumayr L, et al. A comparison of conservative and aggressive transfusion regimens in the perioperative management of sickle cell disease. N Engl J Med. 333:1995;206-213
134. Koshy M, Weiner SJ, Miller ST, et al. Surgery and anesthesia in sickle cell disease: Cooperative Study of sickle cell disease. Blood. 86:1995;3676-3684
135. Serjeant GR. Chronic transfusion programs in sickle cell disease: problem or panacea? Br J Haematol. 97:1997;253-255
136. Griffin TC, Buchanan GR. Elective surgery in children with sickle cell disease without preoperative blood transfusion. J Pediatr Surg. 28:1993;681-685
137. Powars DR, Sandhu M, Niland-Weiss J, Johnson C, Bruce S, Manning PR. Pregnancy in sickle cell disease. Obstet Gynecol. 67:1986;217-228
138. Serjeant GR, Loy LL, Crowther M, Hambleton IR, Thame M. Outcome of pregnancy in homozygous sickle cell disease. Obstet Gynecol. 103:2004;1278-1285
139. Rahimy MC, Gangbo A, Adjou R, Deguenon C, Goussanou S, Alihonou E. Effect of active prenatal management on pregnancy outcome in sickle cell disease in an African setting. Blood. 96:2000;1685-1689
140. Koshy M, Burd L, Wallace D, Moawad A, Baron J. Prophylactic red-cell transfusions in patients with sickle cell disease: a randomized cooperative study. N Engl J Med. 319:1988;1447-1452
141. Vichinsky EP, ed. Transfusion-related iron overload in sickle cell anemia. Semin Hematol 2001; 38 (suppl 1): 1-84.
142. Steinberg MH, Rodgers GP. Pharmacologic modulation of fetal hemoglobin. Medicine. 80:2001;328-344
143. Steinberg MH, Barton F, Castro O, et al. Effect of hydroxyurea on mortality and morbidity in adult sickle cell anemia. JAMA. 289:2003;1645-1651
144. Maier-Redelsperger M, Labie D, Elion J. Long-term hydroxyurea treatment in young sickle cell patients. Curr Opin Hematol. 6:1999;115-120
145. Ferster A, Tahriri P, Vermylen C, et al. Five years of experience with hydroxyurea in children and young adults with sickle cell disease. Blood. 97:2001;3628-3632
146. Wang WC, Wynn LW, Rogers ZR, Scott JP, Lane PA, Ware RE. A two-year pilot trial of hydroxyurea in very young children with sickle cell anemia. J Pediatr. 139:2001;790-796
147. Miller MK, Zimmerman SA, Schultz WH, Ware RE. Hydroxyurea therapy for pediatric patients with hemoglobin SC disease. J Pediatr Hematol Oncol. 23:2001;306-308
148. Steinberg MH, Nagel RL, Brugnara C. Cellular effects of hydroxyurea in Hb SC disease. Br J Haematol. 98:1997;838-844
149. Ware RE, Eggleston B, Redding-Lallinger R, et al. Predictors of fetal hemoglobin response in children with sickle cell anemia receiving hydroxyurea therapy. Blood. 1999:2002;10-14
150. Atweh GF, Sutton M, Nassif I, et al. Sustained induction of fetal hemoglobin by pulse butyrate therapy in sickle cell disease. Blood. 93:1999;1790-1797
151. DeSimone J, Koshy M, Dorn L, et al. Maintenance of elevated fetal hemoglobin levels by decitabine during dose interval treatment of sickle cell anemia. Blood. 99:2002;3905-3908
152. Saunthararajah Y, Hillery CA, Lavelle D, et al. Effects of 5-aza-2′-deoxycytidine on fetal hemoglobin levels, red cell adhesion, and hematopoietic differentiation in patients with sickle cell disease. Blood. 102:2003;3865-3870
153. Belcher JD, Bryant CJ, Nguyen J, et al. Transgenic sickle mice have vascular inflammation. Blood. 101:2003;3953-3959
154. Solovey AA, Solovey AN, Harkness J, Hebbel RP. Modulation of endothelial cell activation in sickle cell disease: a pilot study. Blood. 97:2001;1937-1941
155. Auphan N, DiDonato JA, Rosette C, Helmberg A, Karin M. Immunosuppression by glucocorticoids: inhibition of NFκB activity through induction of IκB synthesis. Science. 270:1995;286-290
156. Griffin TC, McIntire D, Buchanan GR. High-dose intravenous methylprednisone therapy for pain in children and adolescents with sickle cell disease. N Engl J Med. 330:1994;733-737
157. Bernini JC, Rogers ZR, Sandler ES, Reisch JS, Quinn CT, Buchanan GR. Beneficial effect of intravenous dexamethasone in children with mild to moderately severe acute chest syndrome complicating sickle cell disease. Blood. 92:1998;3082-3089
158. Orringer EP, Casella JF, Ataga KI, et al. Purified poloxamer 188 for treatment of acute vaso-occlusive crisis of sickle cell disease: a randomized controlled trial. JAMA. 286:2001;2099-2106
159. Styles LA, Lubin B, Vichinsky E, et al. Decrease of very late activation antigen-4 and CD36 on reticulocytes in sickle cell patients treated with hydroxyurea. Blood. 89:1997;2554-2559
160. Setty BNY, Kulkarni S, Dampier CD, Stuart M. Fetal hemoglobin in sickle cell anemia relationship to erythrocyte adhesion markers and adhesion. Blood. 97:2001;2568-2573
161. Harlan JM. Introduction: anti-adhesion therapy in sickle cell disease. Blood. 95:2000;365-367
162. Osarogiagbon UR, Choong S, Belcher J, Vercellotti GM, Paller MS, Hebbel RP. Reperfusion injury pathophysiology in sickle transgenic mice. Blood. 96:2000;314-320
163. Gladwin MT, Schechter A, Ognibene FP, et al. Divergent nitric oxide bioavailability in men and women with sickle cell disease. Circulation. 107:2003;271-278
164. Reiter CD, Wang X, Tanus-Santos J, et al. Cell-free hemoglobin limits nitric oxide bioavailability in sickle cell disease. Nat Med. 8:2002;1383-1389
165. Aslan M, Ryan TM, Adler B, et al. Oxygen radical inhibition of nitric oxide-dependent vascular function in sickle cell disease. Proc Natl Acad Sci USA. 98:2001;15215-15220
166. Haque AK, Gokhale S, Rampy BA, Adegboyega P, Duarte A, Saldana MJ. Pulmonary hypertension in sickle cell hemoglobinopathy: a clinicopathologic study of 20 cases. Hum Pathol. 33:2002;1037-1043
167. Gladwin MT, Sachdev V, Jison ML, et al. Pulmonary hypertension as a risk factor for death in patients with sickle cell disease. N Engl J Med. 350:2004;886-895
168. Weiner DL, Hibberd PL, Betit P, Cooper AB, Botelho CA, Brugnara C. Preliminary assessment of inhaled nitric oxide for acute vaso-occlusive crisis in pediatric patients with sickle cell disease. JAMA. 289:2003;1136-1142
169. Clarkson P, Adams MR, Powe AJ, et al. Oral L-arginine improves endothelium-dependent dilation in hypercholesterolemic young adults. J Clin Invest. 97:1996;1989-1994
170. Morris CR, Morris SM Jr, Hagar W, et al. Arginine therapy: a new treatment for pulmonary hypertension in sickle cell disease? Am J Respir Crit Care Med. 168:2003;63-69
171. Morris CR, Kuypers FA, Larkin S, et al. Arginine therapy: a novel strategy to induce nitric oxide production in sickle cell disease. Br J Haematol. 111:2000;498-500
172. Romero JR, Suzuka SM, Nagel RL, Fabry ME. Arginine supplementation of sickle transgenic mice reduces red cell density and Gardos channel activity. Blood. 99:2002;1103-1108
173. Hoppe CC, Walters MC. Bone marrow transplantation in sickle cell anemia. Curr Opin Oncol. 13:2001;85-90
174. Amrolia P, Almeida A, Halsey C, Roberts IA, Davies SC. Therapeutic challenges in childhood sickle cell disease. Br J Haematol. 120:2003;725-736
175. Pawliuk R, Westerman KA, Fabry ME, et al. Correction of sickle cell disease in transgenic mouse models by gene therapy. Science. 294:2001;2368-2371